FEATURED

Mantle Cell Lymphoma: The Treatment Landscape

Relapse is inevitable in mantle cell lymphoma. Treatment of relapsed MCL is, however, evolving, with several treatment regimen options, though ibrutinib is still the standard of care.

microRNAs and the Future of RCC

With researchers around the world directing their attention at the role and potential of miRNAs in RCC diagnosis and therapy, our understanding of the molecules is accelerating.

Malware in Medicine: Prevention Is Key

The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.

Herb-drug, Drug-drug Interactions

Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.

Immune-mediated Hepatitis: Challenges in Management

The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.

Q&A With Adam Brufsky, MD, PhD

Cancer Therapy Advisor asked Dr Brufsky to comment on the evolving role of endocrine-based therapy for this patient population, including combinations based on molecular and genetic profiling.

Active Surveillance and Watchful Waiting

Active surveillance provides an important alternative to immediate treatment for early-stage, low-risk prostate cancers. For men with a relatively short life expectancy, watchful waiting is recommended.

Low-fat Diet and Breast Cancer

Data suggest that a low-fat diet with an increase in vegetable and fruit intake may lower the risk of all-cause mortality among women with breast cancer.

Adverse Effects of Sarcoma Treatment

Adverse events observed in sarcoma survivors highlights the increased need for new, safe treatments, as complications may not be seen until years after the completion of therapy.

FDA: Drug Prices, Cancer Treatment

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

In ER+, early-stage breast cancer

Individualizing treatment with extended adjuvant endocrine therapy

For the treatment of metastatic non-small

Biomarker testing for epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations is important when considering a first-line therapy

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

In ER+, early-stage breast cancer

Experts discuss risk vs benefit of extended adjuvant endocrine therapy

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

Latest Features

Mantle Cell Lymphoma: Evaluating the Treatment Landscape

Mantle Cell Lymphoma: Evaluating the Treatment Landscape

Relapse is inevitable in mantle cell lymphoma. Treatment of relapsed MCL is, however, evolving, with several treatment regimen options, though ibrutinib is still the standard of care.

microRNAs and the Future of Renal Cell Carcinoma Treatment

microRNAs and the Future of Renal Cell Carcinoma Treatment

With researchers around the world directing their attention at the role and potential of miRNAs in RCC diagnosis and therapy, our understanding of the molecules is accelerating.

Malware in Medicine: Prevention Is Key to Protection

Malware in Medicine: Prevention Is Key to Protection

The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.

Drug-herb and Drug-drug Interactions in Oncology

Drug-herb and Drug-drug Interactions in Oncology

Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.

Immune-mediated Hepatitis: Challenges in Management

Immune-mediated Hepatitis: Challenges in Management

The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters